Recent major deals Roche & Zealand Pharma: a $5.3 billion partnership to develop an amylin analog - a next generation treatment targeting appetite regulation AbbVie & Gubra: a $350 million licensing deal for an experimental obesity therapy, likely with multi-receptor or novel pathway targeting These deals highlight a significant shift in research strategy Rather than relying solely on internal R&D or acquisitions, pharma companies are leveraging biotech partnerships to accelerate innovation
Why It Matters This is the first human study to show that GLP-1 medications may help the body burn visceral fat more actively not just reduce calories in.That means the weight loss benefits could be coming from both appetite control and a metabolic boost
In the UK, new medicines must receive a marketing authorisation from the MHRA before they can be legally prescribed or dispensed
A recent Office of the Inspector General report [118] found that, in the third quarter of 2024, a typical beneficiary received 82 units of skin substitutes, meaning that the typical $74 add-on amount per unit alone was worth over $6,000 per patient
10.2337/dbi18-0008 [DOI] [PubMed] [Google Scholar] 77.Hamdani N, van der Velden J
